OBJECTIVES The purpose of this study was to examine the role of mexiletine, a late sodium current (I Na-L ) blocker, in acute termination of torsades de pointes (TdP) refractory to conventional therapy in acquired long QT syndromes (LQTS).
T orsades de pointes (TdP) is a polymorphic form of ventricular tachycardia seen in the setting of QT interval prolongation that was first described by Dessertenne in 1966 (1). Other electrocardiographic manifestations that accompany significant QT prolongation include macro T-wave alternans (TWA) (2) . Since the first description, the list of acquired pathologic conditions that lead to QT prolongation and TdP has markedly expanded. TdP is caused by either congenital or acquired long QT syndromes (LQTS).
Whereas prescription drugs account for the majority of cases of acquired LQTS (3), other causes include post-myocardial infarction QT prolongation (4) , electrolyte disturbances (hypokalemia, hypomagnesemia, and hypocalcemia), takotsubo cardiomyopathy (5), pheochromocytoma (6) , and intracranial bleeding (7).
First-line treatment approaches to TdP include removal of the offending causes, the use of intravenous magnesium, maintenance of high-normal serum potassium level, and avoidance of QT-prolonging agents. In some refractory cases, isoproterenol infusion or temporary transvenous ventricular pacing may be required to increase heart rate, thereby to shorten the QT interval (8, 9) .
TdP often occurs during bradycardia or after a long pause that exaggerates the QT interval prolongation (10, 11) . Additionally, bradycardia and pauses increase the period from the peak to the end of the T-wave (T p-e ), which represents transmural dispersion of repolarization, during which ventricular muscle cells are most vulnerable to TdP.
Recent basic research has shown that late sodium (I Na-L ) is the key current contributing to rate adaptation of ventricular repolarization (12, 13) . When I Na-L is large, ventricular repolarization, which is represented by the QT interval on the surface electrocardiogram (ECG), exhibits more prominent rate dependence.
Conversely, delayed ventricular repolarization, irrespective of its etiology, can amplify I Na-L by slowing its inactivation and is associated with bradycardia or pause-dependent exacerbation of QT and T p-e prolongation (12, 14) . Therefore, inhibition of I Na-L could be a common pharmacotherapeutic target for termination and prevention of TdP in LQTS.
Mexiletine, a Class Ib antiarrhythmic drug, is a potent blocker of I Na-L even at therapeutic plasma concentrations (IC50-half maximum inhibitory concentration-of INa-L by mexiletine is 17.6 AE 1.9 mmol/l) compared with its relatively weak effect on the fast sodium current (15, 16) . Mexiletine was shown in animal models to shorten drug-induced QT prolongation (17) (18) (19) . Mexiletine also shortens QT interval in patients with congenital LQT3 caused by a gain-offunction mutation in I Na-L (20) and is therefore recommended as an additional therapy to beta-blockers in this subset of patients (21) . However, clinical information regarding the use of an I Na-L blocker in acute termination of TdP in acquired cases of LQTS that are not necessarily related to an increase in I Na-L is lacking.
Although ranolazine also blocks I Na-L, it inhibits the rapidly activating delayed rectifier potassium (I kr ) current and may prolong the QT interval, thus limiting the potential of its use in this subset of patients.
Therefore, we investigated the role of I Na-L blockade with mexiletine in the acute termination of TdP in several patients with acquired causes of LQTS.
The effect of mexiletine on TWA was also studied. Badri et al.
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Among the 12 patients, 2 patients had TdP refractory to intravenous isoproterenol infusion, and a third patient's condition was refractory to temporary transvenous pacing. These 12 patients were then treated with oral mexiletine, 150 to 450 mg/day orally. Tp-e/QT ratio ¼ ratio between the interval from the peak to the end of the T-wave and the QT interval.
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Mexiletine exhibited no significant effect on QRS duration (105.1 AE 9 ms in pre-mexiletine vs. 105 AE 5.9 ms in post-mexiletine findings, p ¼ 0.9).
EFFECTS OF MEXILETINE ON QT-RR SLOPES.
TdP is often initiated after a characteristic short-long-short ventricular cycle sequence. As shown in Figure 3A ,
QT and T p-e intervals were disproportionally prolonged after a longer RR interval (pause) that manifested as a larger T-wave with an increased T p-e interval and facilitated the development of a R-on-T ectopic beat capable of initiating TdP. Mexiletine blunted the change in the T-wave amplitude and T p-e duration after the pause ( Figure 3B ).
The QT-RR slopes were generated by plotting 112 pre-mexiletine QT-RR pairs and 118 post-mexiletine QT-RR pairs in 8 patients for whom detailed telemetry tracings were available. In all 8 patients, mexiletine treatment led to significant blunting of QT-RR relationship slopes ( Figures 3C and 3D ). Badri et al.
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weak repolarization reserve such as M cells (27); 2) facilitation of the development of EADs (28, 29) ; and 3) enhancement of the QT-RR relationship (12, 14) . Electrocardiogram (ECG) strips of 4 cases displaying long QT pre-mexiletine, followed by torsade de pointes (TdP), and post-mexiletine ECG strips. In case A, the post-mexiletine ECG was recorded 24 h after the first dose and after a total of 400 mg. In case B, it was recorded 15 h after the first dose and after a total of 300 mg.
In case C, the post-mexiletine ECG was recorded 25 h after the first dose and after 600 mg of mexiletine. In case D, the post-mexiletine ECG was recorded 23 h after the first dose and after a total of 600 mg. Note that all 4 episodes of TdP occurred following a long-short interval.
Badri et al. Ranolazine is also an I Na-L blocker that has been shown to suppress TdP in animal experiments (33) .
The major reason that we chose mexiletine instead of ranolazine is that ranolazine also blocks I Kr (36) and can prolong the QT interval in patients (37) . Additionally, ranolazine was linked to QT prolongation and TdP in a recent case report (38) . Lidocaine,
another Class Ib agent that also blocks late I Na-L (39), shortens the QT interval, and in a some cases it was shown to be effective in treatment of long QT and TdP (40, 41) . However, mexiletine inhibits I Na-L more selectively than does lidocaine. IC 50 of mexiletine for I Na-L is 17.6 mmol/l, which is close to its therapeutic plasma concentration (15) , whereas IC 50 of lidocaine is 89 mmol/l (39) , significantly higher than its therapeutic plasma concentration (42) . However, it would be important to compare the efficacy of lidocaine with that of mexiletine in future clinical studies because the intravenous administration route of lidocaine would be advantageous in critically ill patients. Badri et al.
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CONCLUSIONS

